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appears often as a result of ovarian teratoma. Since ovar-
ian tumors and nervous tissue share common antigens 
(e.g., cdr2, NMDAR), autoimmune etiology is a probable 
mechanism of these neurologic disorders. The concept of 
cross-presentation, however, seems insufficient to explain 
entirely the emergence of PNS. Early resection of ovar-
ian tumors is a significant part of PNS management and 
improves the outcome.
Conclusions  The diagnosis of PNS potentially associated 
with ovarian tumor indicates a need for a thorough diagnos-
tic procedure in search of the neoplasm. In some patients, 
explorative laparoscopy/laparotomy can be considered.
Keywords  Ovarian cancer · Ovarian teratoma · 
Paraneoplastic cerebellar degeneration · Anti-NMDAR 
encephalitis
Key points
•	 PNS precede clinical manifestation of ovarian tumors 
and enable their diagnosis at an early stage.
•	 Paraneoplastic cerebellar degeneration (PCD) can coex-
ist with ovarian carcinoma.
•	 Anti-NMDAR antibodies detected in patient affected 
with encephalitis are highly suggestive of ovarian tera-
toma.
•	 Ovarian tumors and nervous tissue share common anti-
gens in PNS (e.g., cdr2, NMDA receptor)—the concept 
of cross-presentation, however, may not be sufficient to 
explain an emergence of PNS.
•	 Cell-mediated immune response plays a role in the 
pathogenesis of PNS.
•	 Antibody-mediated immune response is a major mecha-
nism of anti-NMDAR encephalitis and other NSAS.
Abstract 
Introduction  Paraneoplastic neurological syndromes 
(PNS) are neurologic deficits triggered by an underlying 
remote tumor. PNS can antedate clinical manifestation of 
ovarian malignancy and enable its diagnosis at an early 
stage. Interestingly, neoplasms associated with PNS are 
less advanced and metastasize less commonly than those 
without PNS. This suggests that PNS may be associated 
with a naturally occurring antitumor response.
Methods  We review the literature on the diagnosis, patho-
genesis and management of PNS associated with ovarian 
tumors: paraneoplastic cerebellar degeneration (PCD) and 
anti-N-methyl-d-aspartate receptor (anti-NMDAR) enceph-
alitis. An approach to the diagnostic workup of underlying 
tumors is discussed.
Results  PCD can precede the manifestation of ovarian 
carcinoma. Anti-NMDAR encephalitis in young women 
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•	 In patients with PNS associated potentially with ovarian 
tumors, transvaginal ultrasound examination and pel-
vic CT scan are indicated—if negative, PET imaging is 
required.
•	 If imaging studies remain normal, explorative laparos-
copy/laparotomy should be considered.
•	 An early resection of ovarian tumors is a significant part 
of PNS management and improves the outcome.
Definition
Paraneoplastic neurological syndromes (PNS) are defined 
as the pathologic involvement of the nervous system in the 
course of malignancy. This entity does not include tumor 
infiltration, compression or metastasis of the nervous sys-
tem (Graus et al. 2004). PNS often precede clinical mani-
festation of a tumor and enable diagnosis at an early stage. 
Interestingly, neoplasms that appear in patients with PNS 
are limited in size and metastasize less commonly than 
those without PNS (Hetzel et al. 1990; Albert and Dar-
nell 2004). These observations suggest that PNS provide 
an example of a naturally occurring antitumor response. 
Ovarian tumors account for about 10 % of malignancies 
associated with PNS (Giometto et al. 2010). Paraneoplas-
tic cerebellar degeneration (PCD), the most common para-
neoplastic neurological syndrome, may coexist with ovar-
ian carcinoma (Giometto et al. 2010). Recently, a group 
of neurologic disorders, neuronal surface antibodies syn-
dromes (NSAS), has been defined (Zuliani et al. 2012). 
They usually affect the central nervous system in the form 
of encephalitis that manifests mainly as behavioral disor-
der and seizures. However, they are rarely related to malig-
nancy. One of NSAS, however, anti-NMDAR encephalitis, 
appears typically in young women with a benign tumor, 
ovarian teratoma.
The diagnosis of PNS is based on criteria defined in 
Graus et al. (2004). This takes into account neurological 
symptoms, presence of a tumor and antibodies associated 
with this condition, referred to as onconeural antibodies 
(Graus et al. 2004). The diagnosis of PNS is a complex pro-
cess that always requires exclusion of primary etiology of 
neurologic symptoms, including among others—vascular 
disorders, infection, nervous tissue tumors or hereditary 
syndromes. The classification of PNS distinguishes “clas-
sical syndromes” and “well-characterized onconeural anti-
bodies” that are the most specific for PNS (Tables 1, 2). 
The term “definite PNS” in contrast to “possible PNS” 
indicates higher probability of the paraneoplastic nature of 
a disorder (Table 3). This differentiation is important since 
definite PNS requires a more intense search for underlying 
tumor. Neuronal surface antibodies syndromes typically 
respond well to immunotherapy. Hence, once the diagnosis 
of anti-NMDAR encephalitis is established, it is classified 
as “definite NSAS” if it is responsive to immunomodula-
tory agents such as steroid and intravenous immunoglobu-
lin and as “probable NSAS” if not responsive (Zuliani et al. 
2012).
Incidence
Paraneoplastic syndromes are rare in cancer patients. 
In the group of 1,465 unselected patients with various 
tumors, the history and physical examination revealed neu-
rologic abnormalities in 96 individuals (Croft and Wilkin-
son 1965). In 55 women with ovarian cancer, neurologic 
disorder was diagnosed in nine patients (Croft and Wilkin-
son  1965). These data should, however, be interpreted 
with caution as since the time this study was performed 
the diagnostic criteria of PNS have evolved markedly. It 
is estimated that paraneoplastic neurological syndromes 
appear in about 1 % of all malignancies (Rees 2004). The 
diagnosis, however, becomes more probable in particular 
contexts—approximately half of patients with non-familial 
cerebellar syndrome of subacute onset suffer from some 
malignancy, primarily ovarian or lung cancer. The criteria 
for NSAS diagnosis were clearly defined in 2012 (Zuliani 
et al. 2012). Antibodies in anti-NMDAR encephalitis typi-
cally associated with ovarian teratoma were described 
for the first time in 2005 (Vitaliani et al. 2005). In over 
3 years, more than 400 cases of NSAS have been reported 
(Dalmau et al. 2011). This entity can affect adolescents 
and children, as well as adults. It is worth mentioning that 
three cases of anti-NMDAR encephalitis occurred dur-
ing pregnancy complicated with ovarian teratoma (Kumar 
et al. 2010). Though PNS are still considered rare, their 
estimates of incidence increase with the improvement in 
diagnostic tools.
Table 1   Classical paraneoplastic syndromes
PNS the most commonly associated with ovarian tumors are in bold 
(Graus et al. 2004)
Classical paraneoplastic neurological syndromes
Encephalomyelitis
Limbic encephalitis
Subacute cerebellar degeneration
Opsoclonus–myoclonus
Subacute sensory neuronopathy
Chronic gastrointestinal pseudo-obstruction
Lambert–Eaton myasthenic syndrome
Dermatomyositis101 J Cancer Res Clin Oncol (2015) 141:99–108 
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Diagnosis
Paraneoplastic neurological syndromes may be diagnosed 
prior to tumor detection. It is worth stressing that a com-
bination of classical PNS and the detection of well-charac-
terized antibodies are known to be involved in PNS, even 
without established diagnosis of malignancy is also referred 
to as definite paraneoplastic disorder (Table 3). In such 
cases, there is an obligation to screen for underlying malig-
nancy (Titulaer et al. 2011). In a group of 55 patients with 
PCD the neurological symptoms antedated the diagnosis of 
a neoplasm in 34 individuals (Peterson et al. 1992). In 18 
out of 19 women with gynecologic cancer, primarily ovar-
ian carcinoma, neurologic pathology preceded the detection 
of malignancy (Hetzel et al. 1990). The time between the 
onset of paraneoplastic syndrome and diagnosis of a tumor 
varies from a few weeks to months or even years (Hetzel 
et al. 1990; Rojas et al. 2000). Thus, PNS symptoms ena-
ble detection of a neoplasm at a very early stage. Rarely, 
paraneoplastic neurological syndrome may emerge after 
completed treatment of ovarian cancer (Forgy et al. 2001; 
Goldstein et al. 2009; Russo et al. 2013). Unfortunately, the 
paraneoplastic reaction is sometimes so intense that it itself 
worsens significantly the patient’s clinical outcome and 
leads to disability (Cao et al. 1999). Paraneoplastic cerebel-
lar syndromes are highly debilitating and often irreversible 
(Mason et al. 1997). By contrast, anti-NMDAR encephali-
tis that affects women with ovarian teratoma responds well 
to tumor resection and subsequent immunotherapy which 
may lead to almost complete recovery.
Clinical presentation
The onset of signs and symptoms of paraneoplastic syn-
drome is usually subacute and develops within a few 
weeks. PCD manifests clinically as cerebellar syndrome. 
The patient suffers from incoordination of movements 
(ataxia), balance and gait disturbances, speech disorder 
(dysarthria) and altered ocular movements (nystagmus, 
often in a downbeat form) (Peterson et al. 1992; Dalmau 
and Rosenfeld 2008). Paraneoplastic neurological syn-
dromes associated with ovarian tumors may also appear as 
a peripheral polyneuropathy with diffuse paresthesia and 
anesthesia (Cao et al. 1999). Young women or children 
with ovarian teratoma can be affected with encephalitis 
that manifests as psychosis, memory loss and behavior dis-
order. It subsequently develops into seizures, dyskinesias 
and autonomic instability (Florance et al. 2009; Tanyi et al. 
2012; Zuliani et al. 2012). Neurologic pathology is often 
highly debilitating and renders many patients either wheel-
chair bound or bedridden (Frings et al. 2005).
Table 2   Onconeural and neuronal surface antibodies
Antibodies detected commonly in PNS associated with ovarian 
tumors are in bold (Graus et al. 2004; Titulaer et al. 2011; Zuliani 
et al. 2012)
Onconeural and neuronal surface antibodies
Well characterized Partly character-
ized
Neuronal surface antibodies
Anti-Hu
Anti‑Yo
Anti‑Ri
Anti-CV2
Anti-Ma
Anti‑amphiphysin
Anti-Tr
Anti-Zic4
Anti-mGluR1
ANNA3
PCA2
Anti-VGKC complex antigens 
(LGI1 or CASPR2)
Anti‑NMDAR
Anti-AMPAR
Anti-GABABR
Anti-GlyR
Anti-VGCC-Ab
Anti-mGluR1
Anti-mGluR5
Table 3   Definite and possible PNS according to diagnostic criteria as published by Graus et al. (2004)
Neurological syndrome with well-characterized antibodies (in bold) is a clinical setting that requires intense search for underlying malignancy 
and often enables its detection at an early stage. Reproduced from ‘Recommended diagnostic criteria for paraneoplastic neurological syndromes’ 
(Graus et al. 2004) with permission from BMJ Publishing Group Ltd.
Definite PNS Possible PNS
Definite and possible diagnosis of PNS
1. A classical syndrome and cancer that develop within 5 years of the 
diagnosis of the neurological disorder
1. A classical syndrome, no onconeural antibodies, no cancer is diag-
nosed, but at high risk for having an underlying tumor
2. A non-classical syndrome that resolves or significantly improves 
after cancer treatment without concomitant immunotherapy provided 
that the syndrome is not susceptible to spontaneous remission
2. A neurological syndrome (classical or not) with partially character-
ized onconeural antibodies and no cancer
3. A non-classical syndrome with onconeural antibodies (well charac-
terized or not) and cancer that develops within 5 years of the diagno-
sis of the neurological disorder
3. A non-classical syndrome, no onconeural antibodies and cancer 
present within 2 years of diagnosis
4. A neurological syndrome (classical or not) with well‑charac‑
terized onconeural antibodies (anti‑Hu, Yo, CV2, Ri, Ma2 or 
amphiphysin) and no cancer102   J Cancer Res Clin Oncol (2015) 141:99–108
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Antibodies
Laboratory analyzes may reveal the presence of onconeu-
ronal antibodies. They are detected by means of an indirect 
immunofluorescence and confirmatory Western or line blot 
(Monstad et al. 2008; Stefens-Stawna et al. 2013). The most 
common type of antibody found in PCD is anti-cdr2 (cere-
bellar degeneration protein-2 antibody) (also known as anti-
Yo) (Anderson et al. 1988; Peterson et al. 1992). Anti-Yo 
antibody seropositive status suggests ovarian cancer, breast 
cancer or other gynecologic malignancies (Peterson et al. 
1992). Infrequently, it can be related to small cell lung can-
cer (Greenlee and Lipton 1986). Recently, new antibodies, 
termed anti-cdr2-like (cdr2L), have been described (Eichler 
et al. 2013). They are reactive against an antigen similar 
to the cdr2 protein, which instead of being cytoplasmic is 
within the cell membrane. The coexistence of antibodies 
to cdr2 and cdr2L is strongly suggestive of definite PNS. 
Surprisingly, PCD has been diagnosed only in patients with 
both antibodies. Paraneoplastic cerebellar syndrome may 
also be associated with anti-Hu antibodies which raises 
suspicion of small cell lung cancer. The detection of anti-
Ri, in turn, suggests an underlying breast cancer. Clinician 
should also take into consideration the diagnosis of lym-
phoma, especially if anti-Tr or anti-mGluR1 antibodies are 
identified (Shams’ili et al. 2003). Interestingly, PCD related 
to anti-Yo antibodies is associated with a worse survival 
due to cancer as compared to other antibodies (Giometto 
et al. 2010). In a group of neuronal surface antibodies syn-
dromes, anti-NMDAR antibodies are strongly indicative 
of ovarian teratoma (Florance et al. 2009; Zuliani et al. 
2012). A substantial number of patients, however, mani-
fest paraneoplastic syndromes unrelated to detection of 
any of the above antibodies (Giometto et al. 2010). In addi-
tion, onconeuronal antibodies appear in some patients with 
ovarian tumors who do not suffer from any neurological 
symptoms. In a group of 181 women with ovarian cancer 
without paraneoplastic syndrome, there were four who had 
anti-Yo and seven who had anti-Ri onconeuronal antibodies 
(Drlicek et al. 1997). The detection of anti-cdr2 antibodies 
in ovarian cancer can be improved by in vitro transcrip-
tion–translation (ITT) of radiolabelled cdr2 protein and 
immunoprecipitation assay (Monstad et al. 2006; Eichler 
et al. 2013). Anti-NMDAR antibodies were detected in 
six out 21 women with teratoma (Michalak et al. 2010). In 
another study, however, anti-NMDAR antibodies were not 
found among 20 neurologically asymptomatic patients with 
ovarian teratoma (Mangler et al. 2013). In general, ovarian 
tumors have high potential to mount an immune response, 
since anti-ovarian autoantibodies are commonly found 
in patients affected with these neoplasms (Szubert et al. 
2012). The detection of antibodies is a major reason to 
raise the suspicion of paraneoplastic syndrome in a patient 
who manifests neurologic symptoms. The type of antibody 
indicates the most probable tumor location, including ovar-
ian cancer and ovarian teratoma.
CSF analysis
An analysis of cerebrospinal fluid (CSF) may display pleo-
cytosis (with a high fraction of lymphocytes), elevated pro-
tein or oligoclonal bands (Frings et al. 2005; Rubello et al. 
2005; Tanyi et al. 2012). Inflammatory changes and anti-
NMDAR antibodies in CSF are frequently present in anti-
NMDAR encephalitis (Vitaliani et al. 2005; Dalmau et al. 
2011). In some patients with PCD, however, no abnormali-
ties have been detected in the CSF (Peterson et al. 1992). 
Though the analysis of CSF often reveals disturbances in 
PNS, it is more informative in anti-NMDAR encephalitis 
than in PCD.
Imaging studies
Magnetic resonance imaging (MRI) in PCD can reveal cer-
ebellar atrophy (Frings et al. 2005). This is consistent with 
pathological postmortem examination, which demonstrates 
significant loss of Purkinje cells and sometimes coexistent 
infiltrates within cerebellum. In some PCD patients, how-
ever, both MRI and CT scan can appear normal (Negishi 
et al. 2013). The fluorodeoxyglucose positron-emission 
tomography (FDG-PET), in turn, imaging most com-
monly reveals cerebellar hypometabolism in PCD (Basu 
and Alavi 2008). Rarely, increased FDG uptake, consistent 
with hypermetabolism, is found in the cerebellar region 
(Choi et al. 2006). Imaging studies are useful mainly for 
differential diagnosis of cerebellar disorders. They help 
to exclude other conditions related to neoplasm that may 
give rise to neurologic symptoms, such as metastases, 
infiltration or vascular complications. MRI in anti-NMDR 
encephalitis in 50 % of patients shows hyperintensity in 
various brain regions, including hippocampus, corpus cal-
losum, temporal and frontal lobes, while in other patients 
the brain image appears normal (Dalmau et al. 2011; Tanyi 
et al. 2012). Though imaging studies are not key to estab-
lish the diagnosis of PNS so far, they are indispensable 
in excluding other conditions responsible for neurologic 
symptoms.
Electroencephalogram (EEG)
The EEG is pathological in the majority of patients with 
anti-NMDAR encephalitis. Abnormally slow and disor-
ganized activity is usually not associated with anomalous 
movements and is unresponsive to antiepileptic therapy 
(Dalmau et al. 2008, 2011). It is consistent with a diffuse 
affection of brain tissue associated with encephalitis.103 J Cancer Res Clin Oncol (2015) 141:99–108 
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Ovarian tumors
PNS can provide an opportunity to investigate naturally 
occurring antitumor immunity (Albert and Darnell 2004). 
In Hu syndrome associated with small cell lung cancer, 
the beneficial effect on survival of early detection due to 
PNS symptoms is well proven and several cases of tumor 
regression have been reported (Darnell and DeAngelis 
1993; Graus et al. 1997). It is a question of debate, how-
ever, whether such a phenomenon applies to all tumors, 
including ovarian cancer. Specific cytotoxic T lymphocytes 
active against cdr2 antigen expressed by ovarian cancer and 
Purkinje cells were identified in peripheral blood in patients 
with PCD (Albert et al. 1998). In some patients with ovar-
ian cancer coexisting with PCD, tumors are limited in size 
and only discovered by microscopic examination (Peterson 
et al. 1992) and have fewer secondary foci in comparison 
with patients without PCD (Hetzel et al. 1990). By histo-
pathological analysis, these tumors are characterized as 
lesion with intense lymphocyte infiltration characteristic of 
an immune response (Peterson et al. 1992; Cao et al. 1999). 
On the other hand, in another study, metastatic disease was 
discovered in 15 out of 18 patients with ovarian cancer and 
PCD, with a median survival of 22 months comparable to 
patients with this form of cancer without PCD (Rojas et al. 
2000). However, it can be hard to estimate an effect of anti-
tumor response on overall survival as nearly half of the 
patients with PNS die from neurologic pathology (Rojas 
et al. 2000). Currently, in PCD associated with ovarian can-
cer, there is no study that explicitly corroborates an effec-
tive antitumor response in terms of prognosis. Further, the 
presence of anti-Yo antibodies in neurologically normal 
patients with ovarian cancer had no influence on survival 
(Drlicek et al. 1997). Hence, the antitumor reaction is prob-
ably effective at the very beginning of tumor development, 
so it less advanced at the time of diagnosis. For unknown 
reason, this response fails to eliminate cancer cells and the 
tumor progresses in a natural aggressive way. The nature of 
antitumor reaction in ovarian cancer coexistent with PCD 
requires more research.
Ovarian tumors associated with anti-NMDAR encepha-
litis include mainly teratomas (Dalmau et al. 2007, 2011). 
Among 91 women with anti-NMDAR encephalitis, 49 had 
ovarian teratoma, including 17 immature tumors and eight 
bilateral ovarian lesions (Dalmau et al. 2008). Cases of sex 
cord–stromal tumors coexistent with anti-NMDAR enceph-
alitis were also reported (Tanyi et al. 2012). Pathological 
studies revealed the presence of nervous tissue with the 
expression of NR2 subunit of NMDA receptor within all 
teratomas (Dalmau et al. 2007, 2008). Significant inflam-
matory infiltrates were also demonstrated in tumors asso-
ciated with anti-NMDAR encephalitis (Tüzün et al. 2009). 
The strong link between anti-NMDAR encephalitis and 
ovarian teratomas incidence can be well explained by the 
cross-presentation of the same antigen.
Pathogenesis
Autoimmune processes undoubtedly take part in pathogen-
esis of PNS (Darnell and Posner 2003). The major hypoth-
esis about the origins of PNS states that tumors express 
antigens that are normally present almost exclusively 
in nervous tissue (Fig. 1). The presentation of neuronal 
antigens by a neoplasm then mounts an intense immune 
response against the tumor which cross-reacts with the 
nervous tissue. To study this hypothesis, investigators have 
searched for onconeuronal antigens common to both nerv-
ous tissue and ovarian tumors. Sera of patients affected 
with PCD were incubated with ovarian cancer tissue from 
individuals without neurologic pathology (Darnell et al. 
2000). In 13 out of 20 tissues, an antigen cdr2 (also called 
Yo protein) was detected in both cerebellar neurons and 
ovarian tumors. This cdr2 antigen was also expressed in 2 
out of 9 breast cancer specimens as well. In one study, the 
protein was found in a normal ovary (Totland et al. 2011). 
It appears that many ovarian cancers express this protein, 
irrespective of the presence of anti-Yo antibodies or mani-
festation of PCD in patients (Darnell et al. 2000; Totland 
et al. 2011). The same relationship was observed in para-
neoplastic neurological syndromes that accompany other 
malignancies, for example, with all small cell lung cancers 
possessing the Hu antigen and only some patients devel-
oping paraneoplastic Hu syndrome (Manley et al. 1995). 
Thus, the presence of onconeuronal antigens and antibodies 
against them does not completely correlate with the origin 
of paraneoplastic reaction.
A detection of onconeuronal antibodies is important 
for the syndrome diagnosis, even though it is not compul-
sory according to diagnostic criteria (Graus et al. 2004). 
The importance of this humoral response in the patho-
mechanism of the disease, however, is unclear. The pas-
sive transfer of antibodies to onconeuronal antigens did 
not lead to neurologic pathology in mouse model (Tanaka 
et al. 1995). Further, immunization of mice with human 
cdr2 antigen induced only antibody production in the 
absence of nervous tissue damage (Tanaka et al. 1994, 
1995). It appears that lymphocytes taken from patients’ 
blood samples were also active against the same antigens 
as antibodies used in diagnosis (Albert et al. 1998; Tanaka 
et al. 1998; Albert et al. 2000; Zaborowski and Michalak 
2013). Specific cytotoxic T lymphocytes have been found 
both in acute and chronic phase of PCD. In PCD associ-
ated with the anti-Yo antibody, a high frequency of HLA 
A24 has been demonstrated (Tanaka and Tanaka 1996). 
This observation suggests that patients in this group are 104   J Cancer Res Clin Oncol (2015) 141:99–108
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more susceptible to autoimmune disorder, which is con-
sistent with the involvement of cytotoxic T lymphocytes. 
It seems, on the other hand, that cell-mediated reaction is 
not always involved in neuronal damage in the course of 
PNS, as pathology studies do not always reveal infiltrates 
that accompany significant neuronal loss (Peterson et al. 
1992) and a number of patients with PCD lack antibod-
ies to onconeuronal antigens (Anderson et al. 1988). In rat 
models of neoplastic disease, cerebellar degeneration with 
Purkinje cell loss has been described without any detect-
able onconeuronal antibodies (Michalak 2008). The recent 
identification of anti-cdr2L antibodies may shed new light 
on the mechanism involved in PCD emergence (Eichler 
et al. 2013), and other, as yet unidentified, onconeural 
antigens may still be discovered. In contrast to the cdr2 
protein that is cytoplasmic, cdr2L antigen is present at the 
cell membrane which may make it more accessible for 
antibody-mediated cytotoxicity. Moreover, when both pre-
sent, anti-cdr2 and anti-cdr2L antibodies had much higher 
avidity than when detected alone. It was consistent with 
the fact that only patients with both antibody types devel-
oped definite PNS in contrast to individuals with either 
anti-cdr2 or anti-cdr2L alone. Cdr2L antigen is expressed 
both in Purkinje cells in cerebellum and in ovarian tumor 
tissue. The role of anti-cdr2L in the mechanism of PCD 
certainly requires further exploration. Taken together, the 
immune reaction, especially cell-mediated response, is 
an important player in the origins of PCD. Contradictory 
results of research in animal models, however, suggest that 
other factors potentially deleterious to nervous tissue may 
also be involved.
Cdr2 is involved in the inhibition of c-myc oncoprotein 
that is widely expressed in many tumors, including ovar-
ian cancer (Okano et al. 1999). Cdr2 sequesters c-myc 
and prevents it from inducing transcription. Cdr2 expres-
sion presumably represses cell proliferation through this 
mechanism, functioning as a tumor suppressor. Elevated 
expression of cdr2 in a tumor tissue may lead to immune 
responses that are also active against nervous tissue. Over-
expression of cdr2 could explain why PCD appears in 
neoplasms that have a less aggressive course, since sup-
pressive mechanisms mediated by cdr2 are constitutively 
more effective. Since in PNS, tumors have often intense 
infiltrates and the significance of cell-mediated immune 
response has been revealed, it is probable that immune 
responses eliminate cancer cells.
By contrast, the pathogenic role of antibodies seems 
well proven in anti-NMDAR encephalitis (Fig. 2). In vitro 
studies revealed that rat neurons incubated with patients’ 
sera containing anti-NMDAR antibodies had reduced 
numbers of NMDA receptors in postsynaptic dendrites. 
This phenomenon was reversible after treatment with 
control CSF (Dalmau et al. 2008). Moreover, in anti-
NMDAR encephalitis, clinical improvement is associated 
with a decrease in NMDR antibody titers (Dalmau et al. 
2008). Pathological studies have demonstrated numerous 
antibody deposits and scarce cell infiltrates in affected 
regions of brain (Tüzün et al. 2009). Notably, the NMDR 
Fig. 1   Ovarian cancer cell expresses cdr 2 antigen that triggers 
immune response against malignancy. The same cdr2 antigen is a 
intracellular protein in Purkinje cell in cerebellum. As a result, cyto-
toxic T lymphocytes (CTL) cross-react against nervous tissue. This 
mechanism represents the prevailing view on the pathogenesis of par-
aneoplastic cerebellar degeneration (PCD) related to ovarian cancer. 
The hallmarks of immune reaction, however, are not detected in all 
patients105 J Cancer Res Clin Oncol (2015) 141:99–108 
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antigens for these antibodies were identified mainly in hip-
pocampus (Vitaliani et al. 2005). In contrast to intracellu-
lar onconeuronal antigens, the target protein was detected 
within the plasma membrane which makes it more acces-
sible to antibodies. A favorable clinical response to 
plasma exchange also provides an argument in favor of 
antibody-mediated mechanism of disease. NMDAR anti-
gen has been found in all ovarian teratomas excised in the 
course of anti-NMDAR encephalitis (Tüzün et al. 2009). 
These observations suggest that the cross-presentation of 
NMDAR antigen in neurons and ovarian tumor leads to 
the anti-NMDAR antibodies production, which induces 
encephalitis.
Management
Diagnosis of PCD should always be associated with a 
search for a primary origin of malignancy. This nervous 
system pathology is most commonly seen in ovarian, breast 
and small cell lung cancers or lymphoma (Peterson et al. 
1992). In some patients, an ovarian tumor can be visualized 
by transvaginal ultrasound or by pelvic CT scan (Negishi 
et al. 2013). The neoplastic disease, however, is frequently 
at a very early stage and consequently a conventional diag-
nostic procedure may appear inconclusive. A number of 
studies show that the use of FDG-PET imaging is more 
sensitive and justified in this clinical context (Frings et al. 
2005). An ovarian tumor that was not visible in transvaginal 
ultrasound appeared evident on the integrated PET–CT 
scan (Marchand et al. 2007). Surgery confirmed the diag-
nosis of a papillar serous adenocarcinoma of an ovary at 
stage IIB. An annual follow-up of another patient with PCD 
uncovered hyperactivity of an axillary region 5 years after 
the onset of neurologic symptoms (Mathew et al. 2006). 
The biopsy was consistent with metastasis of breast cancer. 
In some patients, combined FDG-PET imaging is the only 
one that can reveal the location of the malignancy (Rubello 
et al. 2005).
It is rather the antigenic specificity than particular neu-
rologic syndromes that is more indicative for tumor loca-
tion (Titulaer et al. 2011). The most specific for diagnosis, 
however, is the combination of both. In patients with anti-
Yo, anti-Ri or anti-amphiphysin antibodies ovarian cancer 
should be suspected. If anti-NMDAR antibody is detected, 
it suggests coexistence of teratoma, including its imma-
ture type. The metanalysis of numerous studies conducted 
by Titulaer et al. (2011) contains conclusions concerning 
management. In all these patients, transvaginal ultrasound 
is the investigation of choice. If it is negative, pelvic com-
puted tomography or magnetic resonance imaging should 
be performed. In patients with antibodies that suggest ovar-
ian cancer, an integrated FDG-PET/CT is indicated. It is 
important to perform it as soon as possible as combined 
PET/CT scan used in this context may significantly reduce 
the delay time to the surgery (Frings et al. 2005). If initial 
investigations do not detect any tumor, it is recommended 
to repeat them every 6 months for 4 years.
Fig. 2   NMDA receptor (NMDAR) is expressed on the surface of 
ovarian teratoma cells. As a result of immune reaction, anti-NNMAR 
antibodies are produced. The same receptor is present at the dendrites 
of neurons in many region of central nervous system. Anti-NMDAR 
antibodies enter nervous tissue through the vasculature and react 
against the target protein. Consequently, neural signaling mediated by 
NMDA receptor is considerably disturbed leading to both psychiatric 
and neurologic symptoms106   J Cancer Res Clin Oncol (2015) 141:99–108
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PNS develop as a result of the malignancy. Thus, it is 
not surprising that the neurological outcome in PCD may 
improve after tumor excision. Subsequent systemic immune 
therapy in the form of intravenous immunoglobulin, ster-
oids and tacrolimus has also proven beneficial (Negi-
shi et al. 2013). In young women affected with NMDR 
encephalitis associated with teratoma, surgical removal 
of the tumor in combination with plasma exchange, ster-
oid and intravenous immunoglobulin may yield almost 
complete recovery (Tanyi et al. 2012). In some patients, a 
second-line immunotherapy (rituximab or cyclophospha-
mide) is necessary (Dalmau et al. 2011). It has been proven 
that early surgery combined with immunotherapy markedly 
improves outcome (Dalmau et al. 2008).
The question arises whether the diagnosis of paraneo-
plastic reaction commonly associated with ovarian tumor 
may itself constitute an indication for surgical manage-
ment. Exhaustive laboratory and imaging investigations 
often remain inconclusive as to the presence and location 
of the tumor. Some reports suggest, however, that explora-
tive surgery may reveal an occult neoplasm. In a group of 
19 patients with both ovarian cancer and paraneoplastic cer-
ebellar syndrome, laparotomy was performed (Hetzel et al. 
1990). In seven women, there were no tumor symptoms and 
the laboratory as well as imaging investigation was normal 
prior to the surgery. The decision on operative management 
was taken exclusively based on the detection of onconeu-
ronal antibodies. Surprisingly, all these patients had high-
grade ovarian adenocarcinoma. Another remarkable obser-
vation made by the authors was either the lack of or limited 
volume of peritoneal invasion that are typical for advance 
ovarian cancer. In another study, laparotomy performed in 
some patients with PCD uncovered solely microscopic foci 
of ovarian cancer (Peterson et al. 1992). These findings 
are consistent with a report of postmortem examination of 
a patient who died due to very severe paraneoplastic reac-
tion affecting the nervous system (BRAIN et al. 1951). It 
revealed two very small ovarian tumors the size of which 
did not exceed 2 cm in diameter. These phenomena suggest 
that paraneoplastic reaction corresponds to an antitumor 
response. The history of a patient with PCD and abnor-
mal CA-125 levels at postmenopausal age has also been 
reported (Mason et al. 1997). Though imaging studies did 
not suggest ovarian pathology, both laparoscopic salpingo-
oophorectomy and endometrial biopsy were performed. 
The pathological examination did not confirm malignancy; 
however, the CA-125 level decreased to normal limits after 
ovarian resection. Another report presented the history 
of a patient with PCD whose retroperitoneal lymph node 
was enlarged to the size of 2.2 cm and Ca125 was highly 
elevated. Though during laparotomy adnexa were normal 
macroscopically, pathological examination revealed the 
presence of a microscopic adenocarcinoma of the fallopian 
tube (Frings et al. 2005). In a 53-year-old patient with 
anti-NMDAR encephalitis whose neurologic and psychiat-
ric condition was deteriorating, the decision of abdominal 
laparoscopy was made in spite of normal abdominal and 
pelvic CT scan. Though both adnexa were macroscopi-
cally normal, the pathologic examination revealed a sex 
cord tumor (Tanyi et al. 2012). In a group of adult women 
affected with anti-NMDAR encephalitis, 56 % had ovar-
ian teratoma (Florance et al. 2009). It should be noted that 
this fraction was significantly lower in adolescents and chil-
dren (31 %). Ovarian resection in patients with PNS with-
out clear diagnosis of cancer can be considered effective in 
terms of both malignancy and neurologic outcome. This can 
have considerable value in neoplasm therapy, for often the 
surgery reveals very early stage disease. It is also suggested 
by some authors that an early management of malignancy 
may prevent a more severe neurologic deterioration that 
may remain irreversible and highly debilitating otherwise 
(Vedeler et al. 2006; Tanyi et al. 2012). It has been con-
firmed that antitumor treatment improves overall survival 
in these patients (Shams’ili et al. 2003). In anti-NMDAR 
encephalitis, an emergent surgery contributes substantially 
to the final outcome and may enable even almost complete 
recovery (Dalmau et al. 2007; Florance et al. 2009; Tanyi 
et al. 2012). Even if serial CT or ultrasound is not sugges-
tive of teratoma, an explorative surgery may prove informa-
tive. In a woman affected with anti-NMDAR encephalitis, 
blind oophorectomy was performed revealing an underlying 
teratoma and the resection was associated with significant 
neurological improvement (Johnson et al. 2010). In con-
trast, an excision of ovaries in combination with immuno-
therapy led to clinical improvement in another patient, but 
surprisingly the pathological examination was normal (Par-
ratt et al. 2009). Taken together, it seems reasonable to per-
form an explorative laparoscopy or laparotomy in patients 
with paraneoplastic cerebellar syndrome or anti-NMDAR 
encephalitis whose imaging studies appear normal. After 
precise exclusion of other neurological aetiologies and con-
sidering the patient’s age, the salpingo-oophorectomy of 
macroscopically normal adnexa may appear beneficial.
Summary
The clinical manifestation of ovarian tumors can be pre-
ceded by neurological deficit, particularly in cases with 
ovarian cancer or teratoma. The detection of onconeural 
antibodies (e.g., anti-Yo) strongly indicates the presence of 
ovarian tumor in patients with neurological deficit. If the 
tumor is not identified, an obligation for systematic screen-
ing exists. Surgery and immunomodulatory treatment are 
considered as the most important management among such 
a group of patients.107 J Cancer Res Clin Oncol (2015) 141:99–108 
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